Both stocks run through our valuation models. Here is how Pfizer (PFIZER) and Eli Lilly and (LLY) compare, as of Aug 18, 2026.
As of Aug 18, 2026, Fair Value Calculator sees Pfizer as the less overvalued of the two: Pfizer trades at ₹4,829 versus a fair value of ₹3,431 (-29%), while Eli Lilly and trades at $1,183 versus $389 (-67%).
Pfizer
PFIZER.NSE · INR · Health Care
-29%
upside to fair value
overvalued
Price₹4,829
Fair Value₹3,431
Quality82/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,183
Fair Value$389
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
PfizerEli Lilly and
Valuation
30.6×P/E (TTM)42.2×
8.30×P/S (TTM)14.67×
4.97×P/B39.94×
19.7×EV/EBITDA30.2×
—PEG1.54×
1.7%Dividend yield0.5%
₹75.00Dividend per share$6.23
Profitability
29%Net margin35%
35%Operating margin49%
17%Return on equity107%
11%Return on assets21%
Growth
6%Revenue growth (YoY)56%
1.3%Avg. growth/yr (3Y)31.7%
2.4%Avg. growth/yr (5Y)21.6%
Balance & size
0.00×Debt / equity1.54×
$2BMarket cap$1.1T
healthyGrowth qualitymixed
Eli Lilly and leads: 6 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Pfizerof which business quality 79 · market factors 50Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
65
85
Quality GrowthAre margins and returns improving?
53
86
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
72
15
Low VolatilityCalm price path (market factor)
89
77
MomentumPrice trend over the last 3–12 months (market factor)
35
76
52W MomentumDistance to the 52-week high (market factor)
29
95
Net IssuanceBuybacks instead of dilution
82
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Pfizer
DCF Models₹4,042
Earnings-Based₹1,544
Dividend Discount₹3,004
Multiples₹3,065
Asset-Based₹616
Growth DCF₹4,082
Economic Profit₹1,799
Growth Earnings₹2,969
24 of 26 models see the stock below the current price.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Pfizer
Bear ₹2,606Fair Value ₹3,431Bull ₹4,123
₹4,829 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,183 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Pfizer · Health Care
Quality score82 · Top 25%
Fair value upside-29% · below median
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-67% · bottom 25%
Bottom line
As of Aug 18, 2026, Fair Value Calculator sees Pfizer as the less overvalued of the two: Pfizer trades at ₹4,829 versus a fair value of ₹3,431 (-29%), while Eli Lilly and trades at $1,183 versus $389 (-67%).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
